| Review of 1027 patients with newly diagnosed multiple myeloma RA Kyle, MA Gertz, TE Witzig, JA Lust, MQ Lacy, A Dispenzieri, ... Mayo clinic proceedings 78 (1), 21-33, 2003 | 3400 | 2003 |
| Improved survival in multiple myeloma and the impact of novel therapies SK Kumar, SV Rajkumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, ... Blood, The Journal of the American Society of Hematology 111 (5), 2516-2520, 2008 | 2869 | 2008 |
| Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients SK Kumar, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, S Pandey, ... Leukemia 28 (5), 1122-1128, 2014 | 1573 | 2014 |
| POEMS syndrome: definitions and long-term outcome: Presented in abstract form at the 41st annual meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999. A Dispenzieri, RA Kyle, MQ Lacy, SV Rajkumar, TM Therneau, DR Larson, ... Blood, The Journal of the American Society of Hematology 101 (7), 2496-2506, 2003 | 1240 | 2003 |
| Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements S Kumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, C Colby, ... Journal of Clinical Oncology 30 (9), 989-995, 2012 | 1171 | 2012 |
| Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis A Dispenzieri, MA Gertz, RA Kyle, MQ Lacy, MF Burritt, TM Therneau, ... Journal of clinical oncology 22 (18), 3751-3757, 2004 | 1065 | 2004 |
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label … J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ... The lancet oncology 14 (11), 1055-1066, 2013 | 1048 | 2013 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 985 | 2012 |
| A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine RA Kyle, MA Gertz, PR Greipp, TE Witzig, JA Lust, MQ Lacy, TM Therneau New England Journal of Medicine 336 (17), 1202-1207, 1997 | 902 | 1997 |
| Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma SV Rajkumar, SR Hayman, MQ Lacy, A Dispenzieri, SM Geyer, B Kabat, ... Blood 106 (13), 4050-4053, 2005 | 886 | 2005 |
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 JR Mikhael, D Dingli, V Roy, CB Reeder, FK Buadi, SR Hayman, ... Mayo Clinic Proceedings 88 (4), 360-376, 2013 | 711 | 2013 |
| Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial PG Richardson, P Sonneveld, M Schuster, D Irwin, E Stadtmauer, T Facon, ... Blood, The Journal of the American Society of Hematology 110 (10), 3557-3560, 2007 | 693 | 2007 |
| Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma SV Rajkumar, S Hayman, MA Gertz, A Dispenzieri, MQ Lacy, PR Greipp, ... Journal of Clinical Oncology 20 (21), 4319-4323, 2002 | 689 | 2002 |
| Clinical implications of t (11; 14)(q13; q32), t (4; 14)(p16. 3; q32), and-17p13 in myeloma patients treated with high-dose therapy MA Gertz, MQ Lacy, A Dispenzieri, PR Greipp, MR Litzow, KJ Henderson, ... Blood 106 (8), 2837-2840, 2005 | 502 | 2005 |
| Prognostic value of bone marrow angiogenesis in multiple myeloma SV Rajkumar, T Leong, PC Roche, R Fonseca, A Dispenzieri, MQ Lacy, ... Clinical cancer research 6 (8), 3111-3116, 2000 | 470 | 2000 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 469 | 2016 |
| Genetic aberrations and survival in plasma cell leukemia RE Tiedemann, N Gonzalez-Paz, RA Kyle, R Santana-Davila, ... Leukemia 22 (5), 1044-1052, 2008 | 465 | 2008 |
| Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study PG Richardson, DS Siegel, R Vij, CC Hofmeister, R Baz, S Jagannath, ... Blood, The Journal of the American Society of Hematology 123 (12), 1826-1832, 2014 | 464 | 2014 |
| The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma R Fonseca, CS Debes-Marun, EB Picken, GW Dewald, SC Bryant, ... Blood 102 (7), 2562-2567, 2003 | 432 | 2003 |
| Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma MQ Lacy, SR Hayman, MA Gertz, A Dispenzieri, F Buadi, S Kumar, ... Journal of Clinical Oncology 27 (30), 5008-5014, 2009 | 431 | 2009 |
